溶瘤病毒
免疫疗法
癌症免疫疗法
嵌合抗原受体
免疫原性细胞死亡
溶瘤腺病毒
医学
癌症
癌症研究
肿瘤微环境
生物
免疫检查点
免疫学
免疫系统
细胞毒性T细胞
细胞因子释放综合征
癌细胞
作者
Michela Muscolini,Evelyne Tassone,John Hiscott
标识
DOI:10.1016/j.cytogfr.2020.07.014
摘要
Recent advances in cancer immunotherapy have renewed interest in oncolytic viruses (OVs) as a synergistic platform for the development of novel antitumor strategies. Cancer cells adopt multiple mechanisms to evade and suppress antitumor immune responses, essentially establishing a non-immunogenic (‘cold’) tumor microenvironment (TME), with poor T-cell infiltration and low mutational burden. Limitations to the efficacy of immunotherapy still exist, especially for a variety of solid tumors, where new approaches are necessary to overcome physical barriers in the TME and to mitigate adverse effects associated with current immunotherapeutics. OVs offer an attractive alternative by inducing direct oncolysis, immunogenic cell death, and immune stimulation. These multimodal mechanisms make OVs well suited to reprogram non-immunogenic tumors and TME into inflamed, immunogenic (‘hot’) tumors; enhanced release of tumor antigens by dying cancer cells is expected to augment T-cell infiltration, thereby eliciting potent antitumor immunity. Advances in virus engineering and understanding of tumor biology have allowed the optimization of OV-tumor selectivity, oncolytic potency, and immune stimulation. However, OV antitumor activity is likely to achieve its greatest potential as part of combinatorial strategies with other immune or cancer therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI